BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year.

The health agency’s top immunization official announced the move Monday in protest, citing Secretary Kennedy’s ...

Over the weekend, the Food and Drug Administration said that Dr. Peter Marks resigned. Marks was the top vaccine regulator.

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on BioNTech SE (BNTX – Research Report) today. The company’s shares ...

Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...